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Follicular	cell-derived	thyroid	carcinoma	is	the	most	
common	endocrine	malignancy,	representing	almost	
2%	of	all	reported	human	cancers.	Papillary	carcinoma	
is	the	most	common,	and	it	accounts	65%	to	80%	of	
the	15,000	annual	thyroid	cancer	cases	in	the	United	
States	[1].	Because,	at	the	time	of	clinical	presenta-
tion,	most	of	the	tumors	are	still	confined	to	the	thyroid	
gland	(TG),	appropriate	surgical	 treatment	achieves	
a	95%	—	5-year	 survival	 [1,	2].	 Follicular	 carcino-
mas	account	between	4%	and	39%	of	all	malignant	
tumors,	and	medullary	 thyroid	carcinoma,	a	relative	
rare	cancer,	account	up	to	10%	of	all	thyroid	cancers,	
is	composed	of	C	(parafollicular)	cells	[1,	3].	Several	
prognostic	factors	have	been	reported	to	be	significant	
in	thyroid	cancers,	such	as	age	of	presentation,	local	
tumor	size,	extrathyroidal	spread,	distant	metastasis,	
and	histology	[3].	Although	certain	histologic	variants	
of	papillary	carcinoma	are	 recognized	 to	behave	 in	
a	more	aggressive	 fashion,	 routine	histopathologic	
parameters	fail	to	prospectively	identify	the	subset	of	
conventional	papillary	carcinomas	that	is	associated	
with	unusually	aggressive	biological	potential.	There-
fore,	early	markers	to	predict	patients	with	a	low	risk	
of	suffering	a	poor	outcome	from	those	with	a	higher	
risk	of	suffering	a	poor	outcome	are	lacking.	
The	ability	 of	malignant	 tumors	 to	metastasize	
depends	on	various	 factors	such	as	 the	capacity	 to	
degrade	 the	extracellular	matrix	 (ECM),	 to	enter	or	
exit	the	blood	circulation,	and	to	proliferate	in	different	
microenvironments.	At	present,	some	families	of	adhe-
sion	receptors	are	known	to	exist,	which	comprise	the	
cadherins,	syndecans,	integrins,	selectins,	immuno-
globulin	supergene	familiy,	and	CD44	[4].	Syndecan-1	
is	a	membrane	proteoglycan	which	functions	in	cell-
extracellular	matrix	adhesion,	cell-cell	adhesion,	cell	
migration,	as	well	as	in	regulation	of	cell	morphology	
[5,	6].	 It	binds	via	heparin	sulfate	chains	to	both	 in-
soluble	molecules	within	the	ECM	including	interstitial	
collagens,	fibronectin,	tenascin,	thrombospondin	and	
growth	factors	such	as	FGF2	[5].	During	organogene-
sis,	syndecan-1	 is	expressed	on	both	epithelial	and	
mesenchymal	 cells,	predominantly	on	 the	 surface	
of	epithelial	cells	 [7],	while	 in	 the	adult	syndecan-1	
expression	is	found	predominantly	on	the	surface	of	
epithelial	cells,	including	those	of	the	skin	[8],	vagina	
[9],	cervix	[10],	gastric	[7]	and	colonic	mucosa	[11].
E-cadherin,	a	120	kDa	glycoprotein	is	a	calcium-
dependent	homophilic	cell	adhesion	molecule	 [12],	
which	plays	a	central	 role	 in	maintaining	epithelial	
integrity,	functioning	in	intercellular	adhesion	and	dif-
ferentiation,	as	well	as	in	establishing	and	maintain-
ing	cell	polarity	and	tissue	architecture	[13,	14].	The	
prototypic	E-cadherin	(also	called	LCAM,	uvomorulin)	
has	been	mapped	on	chromosome	16q22.1	[4,	15].	
A	mechanical	linkage	at	the	zonula	adherens	between	
E-cadherin	and	cytoskeleton	actin	filaments	mediated	
by	catenins	is	critical	for	normal	E-cadherin	function	
[4,	12].	Failure	of	E-cadherin/catenin	complex	assemb-
ly	and	failure	of	proper	actin	cytoskeleton	connection	
results	in	loss	of	adhesion	[16].	Changes	in	E-cadherin	
function	are	evident	 in	morphogenetic	events	asso-
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ciated	with	cellular	 rearrangement,	movement	and	
wound	healing	[17].
Malignant	epithelial	neoplasms	develop	with	con-
comitant	changes	 in	cellular	adhesion,	cell	motility	
and	changes	in	the	ECM	environment	[16].	This	sug-
gests	 that	 the	 function	and	expression	of	adhesion	
molecules	may	also	change	during	malignant	trans-
formation	as	it	has	been	previously	reported	[8,	18].	
Syndecan-1	may	play	a	pivotal	role	in	limiting	tumor	
growth	and	invasive	capacity	through	its	action	as	a	
receptor	 for	ECM.	The	ability	 to	 invade	 the	ECM	 is	
important	 to	neoplastic	cells	[19].	During	malignant	
progression,	syndecan-1	expression	 is	 lost	on	cells	
exhibiting	an	invasive	phenotype	[20].	In	addition,	cells	
which	normally	 invade	 type	 I	collagen	gels,	 in vitro,	
are	rendered	non-invasive	following	their	transfection	
with	a	cDNA	 for	 syndecan-1,	 thus	providing	direct	
evidence	that	loss	of	syndecan-1	expression	may	be	
an	essential	element	in	the	process	of	invasion	[21].	
Loss	of	E-cadherin	mediated	 intercellular	adhesion	
is	also	important	factor	in	tumor	pathogenesis	[22].	
E-cadherin	deficiency	in	tumors	leads	to	changes	in	
motility	and	morphology,	and,	as	such,	E-cadherin	
is	considered	 to	have	a	 tumor	suppressor	 function	
[16].	Numerous	studies	have	shown	that	E-cadherin	
function	 is	 frequently	 inactivated	 in	cancers	of	 the	
breast	 [23],	colon	[12],	ovarian	[24],	stomach	[25],	
liver	[12],	esophagus	[12],	endometrium	[26],	kidney	
[12],	lung	[27]	and	thyroid	[28].	E-cadherin	has	been	
found	to	stain	moderately,	and	in	some	cases	strongly	
in	well-differentiated	carcinomas,	which	maintain	their	
intercellular	adhesion	and	thus	are	less	invasive,	and	
to	stain	weakly	 in	poorly	differentiated	carcinomas,	
which	have	lost	their	adhesivity	[22].
The	purpose	of	this	study	was	to	clarify	the	role	and	
alterations	of	syndecan-1	expression	in	comparison	
with	those	of	E-cadherin	 in	different	cellular	pheno-
types	of	 thyroid	neoplasms,	by	using	 immunohisto-
chemical	staining.
mATERIAl AND mETHoDs
Representative	 histological	 slides	 and	paraffin	
blocks	were	retrieved	from	the	files	of	the	Departments	
of	Forensic	Pathology	and	Pathology,	of	the	Medical	
School	of	 the	University	of	 Ioannina.	The	mean	age	
of	patients	was	54	(range	21–86	years).	Samples	in-
cluded	in	this	study	consisted	of	normal	thyroid	gland	
(n	=	20),	hyperplastic	disorders	(nodular	hyperplasias,	
n	=	23;	adenomatous	hyperplasias,	n	=	17),	adenomas	
(microfollicular	 type,	 n	=	10;	macrofollicular	 type,	
n	=	18;	 7	 cases	of	mixed	adenomas,	 and	5	cases	
of	Hurthle’s	adenomas)	and	carcinomas	 (papillary,	
n	=	18;	papillary	microcarcinomas	n	=	14;	 follicular,	
n	=	7;	medullary	carcinomas,	n	=	3	cases;	Hurthle’s	
carcinomas,	n	=	2,	poorly	differentiated	carcinomas,	
n	=	5,	and	finally,	anaplastic	carcinomas,	n	=	6)	were	
collected	and	classified	according	to	histopathological	
criteria	by	the	World	Health	Organization	committee	
(WHO)	[29].	Normal	thyroid	tissue	samples	were	ob-
tained	from	autopsies	with	their	relatives’	consent.	The	
average	of	the	tumor	size	was	2.5	cm	(1.8	to	3.1	cm)	
from	 conventional	 papillary	 carcinomas;	 0.7	 cm	
(0.3–1.0	cm)	from	papillary	microcarcinomas;	2.3	cm	
(1.5–2.8	cm)	from	follicular	and	medullary	carcinomas;	
and	3.5	cm	(3.5–6.4	cm)	from	poorly	differentiated	and	
anaplastic	carcinomas.
Immunohistochemistry. For	 immunohisto-
chemical	analysis	the	specimens	were	cut	at	4	μm	on	
poly-l-lysine	slides.	Syndecan-1	was	stained	using	
mouse	monoclonal	antibody	against	human	synde-
can-1	 (DL-101;	Santa	Cruz	Biotechnology,	USA).	 In	
the	study,	E-cadherin,	a	monoclonal	mouse	antibody,	
which	 recognizes	an	epitope	of	human	E-cadherin,	
was	used	(Biotechnology,	Santa	Cruz,	USA).	The	de-
paraffinized	and	rehydrated	sections	were	heat	treated	
in	10	mmol	citrate	buffer	(pH	=	6.0)	for	40	min	at	95	°C	
for	antigen	retrieval	before	staining.	After	endogenous	
peroxidase	blocking	and	 incubation	 in	normal	goat	
serum	for	20	min,	 these	sections	were	 incubated	at	
4	°C	overnight	with	primary	antibodies	 (syndecan-1	
antibody	 (1	 :	100	dilution)	and	E-cadherin	 (1	 :	100	
dilution)).	After	rinsing	in	PBS,	they	were	treated	with	
streptavidin	—	biotin	—	peroxidase	complex	technique	
(DAKO	Co.,	Glostrup,	Denmark).	The	peroxidase	re-
action	was	visualized	by	 incubating	the	section	with	
3,3� -diaminobenzidine	tetrahydrochloride	(DAB,	from	
DAKO).	The	sections	were	counterstained	with	Harri’s	
haematoxylin.	Sections	of	normal	skin	were	used	as	
positive	controls.	Omission	of	the	primary	antibodies	in	
a	matched	serial	normal	tissue	section	(which	lacks	the	
specific	staining	of	the	respective	primary	antibody)	
was	used	as	a	negative	control.	
Scoring of immunostaining. All	sections	were	first	
screened	 to	disclose	 the	areas	with	well-preserved	
tissue	architecture	and	cell	morphology	for	scoring	of	
immunoreactivity.	Necrotic	tumor	areas	or	areas	with	
deterioration	of	tissue	morphology	due	to	processing	
were	discarded	in	the	analysis.	Immunoreactivity	for	
syndecan-1	and	E-cadherin	was	assessed	by	 two	
observers,	(AM,	EI)	independently,	and	using	micro-
scope	(Olympus,	x	40	objective)	and	scored	using	a	
semi-quantitative	approach.	Assessment	of	 synde-
can-1	and	E-cadherin	expression	was	done	without	
any	knowledge	of	the	slide	examined.	Differences	in	
interpretation	were	reconciled	by	re-review	of	slides	
separately	or	jointly	at	a	double-headed	microscope.	
The	specimens	were	classified	according	to	intensity,	
the	localization,	and	the	distribution	of	staining.	Stain-
ing	 intensity	was	classified	as	absent	 (–),	weak	(+),	
moderate	(++),	and	strong	(+++).	Cellular	localization	
of	staining	was	noted	as	diffuse	cytoplasmic	or	staining	
of	cell-cell	contact	sites	or	in	both.	Distribution	of	stain-
ing	was	classified	as	homogeneous	(uniform	staining	
of	cells),	 focal	 (areas	of	positively	stained	cells)	or	
heterogeneous	 (scattered	positively	and	negatively	
stained	cells).
Statistical analysis. To	compare	morphological	
features	and	proteins	expression	data	Superior	Per-
formance	Software	System	(SPSS),	software	10.0	for	
windows	Inc.,	(1999)	was	used.	Significant	differences	
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between	 the	expression	of	 the	 target	protein	was	
computed	by	the	Fisher	test	for	paired	or	non-paired	
values	or	ANOVA	test.	P	values	≤	0.05	were	considered	
statistically	significant.
REsulTs
Syndecan-1, E-cadherin immunoreactivity 
in normal thyroid tissue. The	epithelial	cells	 in	all	
normal	 thyroid	 tissue	specimens	examined	showed	
distinct	 to	moderate	 syndecan-1	 and	E-cadherin	
immunoreactivity.	The	staining	 intensity	was	strong	
in	85%	and	75%	of	 the	cases	 respectively.	This	 im-
munoreactivity	was	less	intense	in	the	flat	cell	 lining	
large	follicules	than	in	cuboidal	or	columnar	cells	lining	
medium-size	or	small	 follicules.	The	 lateral	borders	
of	epithelial	cells	exhibit	more	 intense	staining	 than	
the	basal	 borders.	With	 respect	 to	 localization	of	
immunostaining,	 syndecan-1	and	E-cadherin	were	
expressed	both	 in	cell	membrane	and	cytoplasm	of	
the	thyrocytes,	with	homogeneous	distribution.	In	our	
study	the	stromal	components	of	normal	thyroid	tissue,	
were	completely	un-reactive	for	both	molecules.	The	
results	are	shown	in	Tables	1	and	2.
Table 1. Immunoreactivity for syndecan-1 in normal, hyperplastic, and 
neoplastic thyroid tissue
Histology Number of cases Total 
Intensity of immunostaining (%)
– + ++ +++
Normal tissue 20 13.3 15 85
Hyperplasias: 
Nodular 
Adenomatous
40
23
17
26.6
15.3
11.3
21.7
35.3
78.2
64.7
Adenomas: 
Macrofollicular 
Microfollicular 
Mixed
Hurtle cell
40
18
10
7
5
26.6
12
6.6
4.6
3.3
11.1
10
27.8
20
14.3
20
27.8
30
42.8
60
33.3
40
42.8
20
Carcinomas: 
Papillary 
Micropapillary 
Follicular 
Hurthle 
Medullary
Poorly differentiated 
Anaplastic
55
18
14
7
2
3
5
6
33.3
12
6.6
4.6
1.3
2.0
9.09
4.0
5.5
7.6
14.3
100
66.6
16.6
23.1
28.5
100
33.3
33.3
50
61.5
57.1
27.7
7.6
Table 2. Immunoreactivity for E-cadherin in normal, hyperplastic 
and neoplastic thyroid tissue
Histology Number of cases Total 
Intensity of immunostaining (%)
– + ++ +++
Normal tissue 20 13.3 25 75
Hyperplasias: 
Nodular 
Adenomatous
40
23
17
26.6
15.3
11.3
13.1
23.5
56.5
64.7
30.4
11.8
Adenomas: 
Macrofollicular 
Microfollicular 
Mixed
Hurtle cell
40
18
10
7
5
26.6
12
6.6
4.6
3.3
5.5 44.4
30
28.5
40
38.8
60
57.1
60
11.1
10
14.2
Carcinomas: 
Papillary 
Micropapillary 
Follicular 
Hurthle 
Medullary
Poorly differentiated 
Anaplastic
55
18
14
7
2
3
5
6
33.3
12
6.6
4.6
1.3
2.0
9.09
4.0
16.6
23.1
28.5
100
83.3
27.7
38.5
28.5
100
33.3
16.6
38.8
30.7
42.9
16.6
7.7
Syndecan-1and E-cadherin immunoreactivity 
in hyperplasias. The	 intensity	of	 syndecan-1	and	
E-cadherin	immunostaining	in	hyperplasias	was	usual-
ly	homogeneous	and	in	some	cases	heterogeneous,	
and	less	intense	than	in	normal	follicular	epithelium.	
The	reduction	of	immunoreactivity	for	both	molecules	
may	be	due	to	flat	cells	lining	large	follicules	fullfilled	
with	colloid.	We	 found	a	statistically	significant	dif-
ference	between	normal	 thyroid	 tissue	and	nodular	
hyperplasias	(p <	0.0001),	 indicating	that	the	 inten-
sity	of	expression	of	syndecan-1	and	E-cadherin	was	
stronger	in	normal	tissue	than	in	hyperplasias.	There	
was	no	statistically	significant	difference	among	the	
types	of	hyperplasia.	Therefore,	E-cadherin	expression	
was	reduced	 in	nodular	hyperplasias	 in	comparison	
with	the	adenomatous	ones	(p =	0.0048).	
Syndecan-1 and E-cadherin expression in ade-
nomas. Membranous	and	cytoplasmatic	staining	of	
syndecan-1	and	E-cadherin	was	displayed	in	the	cases	
of	adenomas	examined.	Differences	in	intensity	were	
seen,	as	well	as	with	the	distribution	of	immunostain-
ing.	The	 immunoreactivity	was	weak	 to	moderate	 in	
83.2%	of	the	cases	for	E-cadherin	and	55.5%	of	the	
cases	for	syndecan-1,	and	strong	in	11.1%	and	33.3%	
respectively.	Reduced	expression	of	both	molecules	
was	associated	with	the	different	histological	type	of	
adenomas.
A	 statistically	 significant	 difference	 between	
adenomas	and	normal	 thyroid	 tissue	 (syndecan-1,	
p	 =	0.001,	and	E-cadherin	p	 =	0.0001)	was	 found.	
In	addition,	no	significant	difference	of	syndecan-1	
and	E-cadherin	localization	among	the	types	of	ade-
nomas	was	observed.	Generally	 the	distribution	of	
syndecan-1	and	E-cadherin	in	adenomas	was	rather	
irregular	than	homogeneous.	In	the	cases	of	microfol-
licular	adenomas	the	distribution	of	syndecan-1	and	
E-cadherin	staining	was	more	homogeneous	than	in	
macrofollicular	adenomas	in	which	the	staining	pattern	
was	irregular.
Syndecan-1 and E-cadherin expression in 
thyroid cancer. Immunoreactivity	for	syndecan-1	was	
observed	at	the	cell-cell	boundaries	and	cytoplasm	in	
papillary	carcinomas	(PCs),	with	weak	expression	in	
27.7%	of	the	specimens,	intermediate	expression	in	
38.8%,	and	high	expression	in	16.6%.	The	lateral	bor-
ders	exhibited	more	intense	staining	than	their	basal	
borders	(Fig.	1).	Immunoreactivity	for	E-cadherin	was	
observed	at	the	cell-cell	boundaries	in	PCs	(Fig.	2).	
The	expression	of	E-cadherin	showed	high	variability	
in	PCs	specimens,	with	no	expression	 in	27.03%	of	
the	cases,	 low	expression	 in	38.5%,	 intermediate	
expression	in	30.7%	and	high	expression	in	3	cases	
(7.7%).	Expression	of	 syndecan-1	and	E-cadherin	
was	observed	 in	 the	cell-cell	 contact	areas	and	 in	
the	cytoplasm	 in	 follicular	 carcinomas	 (FCs)	 cells	
with	moderate	expression	 in	42.9%	 for	E-cadherin	
and	54.1%	 for	syndecan-1.	None	of	 the	medullary	
carcinomas	specimens	showed	any	immunoreactivity	
for	syndecan-1	and	E-cadherin.	Poorly	differentiated	
carcinomas	showed	weakly	 immunostaining	of	both	
syndecan-1	and	E-cadherin,	in	the	same	proportion	
(only	2	samples).	Undifferentiated	or	anaplastic	car-
cinomas	(UCs)	are	composed	of	varying	proportions	
of	spindle,	polygonal	and	giant	cells.	Immunoreactivity	
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for	syndecan-1	and	E-cadherin	was	observed	weakly	
in	only	one	case	of	UCs	(16.6%)	for	E-cadherin,	and	
in	 two	cases	 (33.3%)	 for	syndecan-1.	Therefore,	 in	
areas	with	differentiation	of	PCs	the	immunoreactivity	
was	more	markedly	positive.	A	small	number	of	 the	
polygonal	or	giant	carcinoma	cells	showed	very	 low	
expression	on	their	membranes.	None	of	the	spindle-
shaped	tumor	cells	expressed	both	molecules.
Fig. 1. A	case	of	papillary	carcinoma	with	moderate	syndecan-1	
immunoreactivity.	Note	the	cell	surface	expression	with	promi-
nent	cell-cell	junction	staining	and	cytoplasmic	staining	in	some	
tumour	cells.	x	400
Fig. 2. E-cadherin	immunoreactivity	was	observed	at	the	cell-
cell	boundaries	in	the	same	case	of	papillary	thyroid	carcinoma.	
x	400
In	carcinomas,	changes	in	the	proportion	of	cells	
with	positive	staining	were	seen,	as	well	as	changes	
in	the	intensity	of	the	membranous	staining.	Analysis	
of	 the	weighted	scores	showed	a	significant	 reduc-
tion	in	staining	for	both	syndecan-1	and	E-cadherin	
in	carcinomas	compared	with	normal	 thyroid	 tissue	
(syndecan-1,	p	=	0.004	and	E-cadherin,	p	=	0.0004),	
hyperplasias	(syndecan-1,	p	<	0.0001	and	E-cadherin,	
p	=	0.0001)	and	finally	with	adenomas	(syndecan-1,	
p	=	0.0068	and	E-cadherin,	p	=	0.006).	The	intensity	
of	E-cadherin	was	 reduced	 in	all	 studied	malignan-
cies.	We	observed	 that	 the	 intensity	of	syndecan-1	
expression	was	moderate	 to	strong	 in	some	cases	
of	well-differentiated	carcinomas,	and	very	weak	or	
absent	in	poorly	differentiated	and	anaplastic	(undif-
ferentiated)	carcinomas.	Some	tumor	epithelial	cells	
showed	a	membrane-dominant	expression	pattern	of	
syndecan-1	staining,	in	which	the	staining	was	stron-
ger	in	a	cell	membrane	than	in	cytoplasm.	No	statistical	
difference	among	the	papillary	and	follicular	types	of	
carcinoma	was	found.	A	statistically	significant	diffe-
rence	between	moderate	to	strong	immunoreactivity	
of	PCs	with	UCs	 (p	=	0.0084)	 for	 syndecan-1	and	
E-cadherin	(p	=	0.0015),	was	observed.	
Correlation between syndecan-1 and E-cadhe-
rin expression. A	statistically	 significant	 relation-
ship	 in	 the	 intensity	of	 syndecan-1	and	E-cadherin	
(p	<	0.0001)	was	found,	due	to	reduction	of	E-cadherin	
expression	in	all	the	examined	samples,	as	well	as	in	
the	localization	of	the	staining	pattern	(p =	0.002)	and	
finally	with	the	distribution	(p =	0.068)	of	immunore-
activity	in	both	molecules.
DIsCussIoN
Syndecan-1	plays	an	 important	 role	 in	cell-cell	
adhesion,	and	many	studies	have	examined	the	role	
of	syndecan-1	in	oncogenesis	[19,	25,	30].	Recent	re-
ports	suggest	a	decreased	expression	of	syndecan-1	
in	different	 types	of	cancers	such	as	hepatocellular	
carcinoma	[31],	 lung	cancer	 [32],	 infiltrating	breast	
cancer	[33],	laryngeal	cancer	[34],	and	carcinoma	of	
the	uterine	cervix	[10].	On	the	other	hand,	there	are	
many	examples	of	carcinomas	in	which	the	occurrence	
of	altered	E-cadherin	expression	has	been	correlated	
with	low	histological	differentiation,	increased	risk	of	
local	 invasion	and	metastatic	disease,	 recurrence,	
and	poor	prognosis	[23,	24,	26,	27,	35,	36].	Although	
E-cadherin	has	been	extensively	studied	 in	 thyroid	
pathologies	[28,	35,	37],	syndecan-1	has	not	been	ad-
dressed	thoroughly.	To	our	knowledge,	there	is	no	data	
that	compare	syndecan-1	and	E-cadherin	expression	
in	each	cellular	phenotype	in	thyroid	pathologies.
We	studied	a	series	of	tissue	samples	representing	
normal	TG,	hyperplastic	lesions,	adenomas	as	well	as	
different	histiotypes	of	carcinomas.	The	present	results	
demonstrate	 that	 the	cell-cell	adhesion	molecules,	
syndecan-1	and	E-cadherin,	are	expressed	strongly	
in	normal	TG.	This	 is	an	expected	 finding	because	
thyrocytes	are	typical	epithelial	cells	for	which	E-cadhe-
rin	and	syndecan-1	are	considered	to	be	specific.	The	
surface	expression	of	 syndecan-1	and	E-cadherin	
was	confined	to	the	basolateral	domain	of	the	plasma	
membrane,	the	area	of	cell-cell	contact.	Thus,	there	
is	both	biochemical	and	functional	evidence	that	syn-
decan-1	and	E-cadherin	may	be	important	in	cell-cell	
adhesion	in	the	thyroid	follicular	epithelium.
In	tissue	of	various	benign	thyroid	diseases,	inclu-
ded	in	the	present	study,	e.g.	hyperplasias,	E-cadherin	
expression	were	moderate	to	strong,	(25%	and	75%	
of	 the	cases,	 respectively)	 and	are	accordingly	 to	
other	reports	[28,	37,	38].	In	our	report,	we	found	that	
syndecan-1	 immunoreactivity	was	strong	 in	normal	
epithelium	and	moderate	 in	hyperplasias	 (85%	and	
78.5%	of	 the	cases,	 respectively).	 In	 follicular	ade-
nomas	syndecan-1	and	E-cadherin	 immunostaining	
was	 reduced	 in	comparison	with	 the	normal	 tissue.	
The	thyroid	follicular	adenoma	consisting	of	Hurthle	
cells	 displayed	a	 reduced	 immunostaining,	which	
was	mainly	cytoplasmic	and	its	localization	might	be	
impaired	due	to	abnormal	subcellular	targeting	of	the	
molecules.
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In	the	present	report,	the	both	molecules,	synde-
can-1	and	E-cadherin	were	expressed	and	impaired	
in	thyroid	carcinomas.	The	staining	was	clearly	detec-
table	 in	 the	majority	of	well-differentiated	papillary	
carcinomas	and	microcarcinomas.	By	contrast,	 in	
medullary,	poorly	differentiated,	and	anaplastic	thyroid	
carcinomas	the	immunoreactivity	was,	in	conformity	
with	differentiated	 tumors,	only	weakly	positive	or	
most	often,	unreactive,	 indicating	 that	 syndecan-1	
and	E-cadherin	are	markers	of	thyroid	differentiation.	
This	 is	further	supported	by	the	fact	that	most	PCs,	
are	generally	known	as	rather	slowly	growing	tumors,	
although	PCs	have	a	highly	metastatic	rate	to	the	re-
gional	lymph	nodes	[3,	39].
This	 is	analogous	to	the	simultaneous	disappea-
rance	of	both	E-cadherin	and	syndecan-1	 from	 the	
embryo	during	loss	of	the	epithelial	phenotype	[40].	
Loss	of	 cell	 surface	syndecan-1	 in	normal	murine	
mammary	 gland	 epithelia	 is	 accompanied	by	 re-
duced	E-cadherin	expression	 [20].	Manipulation	of	
either	syndecan-1	or	E-cadherin	expression	seems	
to	suggest	that	E-cadherin	regulates	syndecan-1	or,	
conversely,	syndecan-1	regulates	E-cadherin	in	epi-
thelial	cells	[40].	When	syndecan-1	is	down	regulated	
by	anti-sense,	 transfection	 in	mammary	epithelial	
tumor	cells,	E-cadherin	expression	is	lost	from	the	cell	
surface,	and	when	E-cadherin	is	expressed	following	
transfection,	syndecan-1	is	upregulated.	[6].	It	may	be	
that	E-cadherin	and	syndecan-1	act	in	concert,	being	
regulated	together,	and	that	suppression	of	both	leads	
to	malignant	transformation	of	epithelial	cells.
Our	results	are	in	contrast	to	findings	in	the	study	
of	Ito	et	al.	[41],	in	which	syndecan-1	was	expressed	
in	both	stromal	and	neoplastic	epithelial	 cells.	The	
authors	found	that	stromal	syndecan-1	expression	was	
observed	more	frequently	in	larger	papillary	carcino-
mas	and	in	poorly	differentiated	than	in	well-differenti-
ated	carcinomas.	These	contradictory	results	may	be	
probably	due	to	the	difference	in	the	sampling	of	the	
cases,	techniques,	methods	of	analysis,	and	besides	
the	use	of	a	different	antibody.	Our	present	 results	
demonstrated	the	reduced	expression	of	syndecan-1	
in	the	epithelia,	from	normal	to	benign	and	malignant	
lesions,	and	the	absence	of	syndecan-1	reaction	in	the	
stromal	components;	syndecan-1	has	been	regarded	
as	an	inhibitor	of	cell	migration	and	metastasis	[5].	
The	potential	mechanisms	 for	 syndecan-1	de-
regulation	in	malignant	progression	include	increased	
protease	activity,	transcriptional	regulation	and	post-
transcriptional	regulation.	Active	shedding	of	synde-
can-1	occurs	from	the	cell	surface	and	may	be	due	
to	increased	protease	activity	within	the	tumor	[42].	
Changes	in	syndecan-1	expression	can	also	be	regu-
lated	by	post-transcriptional	mechanisms,	 including	
suppression	and	alteration	of	glycosylation,	although	
these	are	not	well	understood	[6].
The	disturbance	in	E-cadherin-mediated	cell	adhe-
sion,	evident	in	the	current	study	of	well-differentiated	
and	undifferentiated	tumors,	is	likely	to	be	attributable	
to	 alterations	 in	 the	E-cadherin/catenin	 complex.	
Possible	mechanisms	for	interfering	with	E-cadherin	
function	 include	 transcriptional	downregulation,	 ty-
rosine	phosphorylation	of	catenins,	mutations	of	the	
E-cadherin	or	catenin	genes	and	abnormal	recycling	
of	E-cadherin	 [12,	 17,	 43].	Surface	expression	of	
E-cadherin	may	be	influenced	by	a	balance	between	
endocytosis	of	membrane	E-cadherin	and	transport	of	
the	protein	to	the	cell	surface.	Le	et	al.	[17]	found	that	
even	at	steady	state	in	confluent	monolayers,	surface	
E-cadherin	 is	subject	 to	endocytosis	and	 recycling.	
The	proportion	of	the	protein	in	the	recycling	pool	is	in-
creased	in	the	absence	of	stable	cell-cell	contacts	[17,	
20].	This	may	be	the	explanation	for	the	other	interest-
ing	 finding	 resulting	 from	our	 investigation,	namely	
the	abnormal	location	of	syndecan-1	and	E-cadherin	
in	some	normal	follicules	and	in	some	tumor	cells.	In	
some	of	them	with	homogeneous	and	heterogeneous	
syndecan-1	and	E-cadherin	expression,	immunoreac-
tive	molecules	were	located	diffusely	in	the	cytoplasm.	
These	findings	suggest	that	functional	disorders	may	
occur	in	syndecan-1	and	E-cadherin	expression.	Fur-
ther	study	of	the	significance	of	cytoplasmic	staining,	
may	reveal	new	insights	into	biology	of	cancer.
In	 conclusion,	 the	present	 study	assessed	 the	
expression	of	E-cadherin	and	syndecan-1,	which	are	
only	one	part	of	the	cell-cell	and	cell-matrix	adhesion	
system	in	the	tumors	of	the	TG.	Both	proteins	expres-
sion	decreased	with	decreasing	cellular	differentiation.	
The	concomitant	 reduction	of	 the	content	of	 these	
molecules	along	with	tumor	dedifferentiation	may	be	
correlated	with	more	aggressive	phenotype.
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ЭКСПРЕССИЯ Е-КАДГЕРИНА И СИНДЕКАНА-1 в тКАНИ 
ЩИтОвИДНОЙ ЖЕЛЕЗЫ ПРИ ЕЕ РАЗЛИчНОЙ ПАтОЛОГИИ
Кадгерины и синдеканы — это трансмембранные гликопротеины, участвующие в межклеточной адгезии и адгезии клеток 
к матриксу. Изменения экспрессии этих молекул играют главную роль в приобретении инвазивного и метастатического 
потенциала злокачественно трансформированными эпителиальными клетками. Цель: оценка роли экспрессии синдекана-1 
и Е-кадгерина в ткани щитовидной железы в норме и при патологии. Методы: образцы ткани для иммуногистохимического 
исследования взяли у 55 больных раком щитовидной железы (ЩЖ), 40 пациентов — с аденомой ЩЖ, 40 — с гипер-
пластическими процессами ЩЖ, контролем служили 20 образцов неизмененной ткани ЩЖ (аутопсия). Результаты: 
экспрессия синдекана-1 и Е-кадгерина в нормальных фолликулярных эпителиальных клетках ЩЖ выражена интенсив-
но, с преимущественной локализацией в базолатеральной мембране. Не отмечали существенных различий в экспрессии 
обеих молекул при гиперпластических процессах по сравнению с аденомами ЩЖ. Однако таковая значительно снижена 
в образцах высокодифференцированной карциномы по сравнению с нормальным эпителием ЩЖ (p = 0,0001 и p = 0,032 
соответственно), а также при низкодифференцированном и анапластическом раке по сравнению с высокодифференци-
рованными опухолями ЩЖ (p = 0,0037 для синдекана-1 и p = 0,075 для Е-кадгерина). Выводы: снижение экспрессии 
синдекана-1 и Е-кадгерина, сопровождающееся снижением способности клеток к дифференциации, может быть частью 
механизма прогрессирования заболеваний ЩЖ.
Ключевые слова: молекулы адгезии, кадгерин, синдекан, рак щитовидной железы.
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